Kodiak Sciences Inc. (KOD) stock
KODNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$97.81+1.01 (+1.04%)
Close on Nov 18, 2026Market cap $6.15BP/E –Yield –
Kodiak Sciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Kodiak Sciences's operating income for the twelve months ending Jun 30, 2026 was -$246.42M. For fiscal 2025 it was -$234.39M. The highest annual figure on record is -$17.15M in fiscal 2016.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$234.39M | – |
| FY2024 | Dec 31, 2024 | -$186.85M | – |
| FY2023 | Dec 31, 2023 | -$277.32M | – |
| FY2022 | Dec 31, 2022 | -$341.38M | – |
| FY2021 | Dec 31, 2021 | -$267.05M | – |
| FY2020 | Dec 31, 2020 | -$136.01M | – |
| FY2019 | Dec 31, 2019 | -$49.19M | – |
| FY2018 | Dec 31, 2018 | -$26.37M | – |
| FY2017 | Dec 31, 2017 | -$25.52M | – |
| FY2016 | Dec 31, 2016 | -$17.15M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$66.84M | – |
| Q1 FY2026 | Mar 31, 2026 | -$59.78M | – |
| Q4 FY2025 | Dec 31, 2025 | -$57.45M | – |
| Q3 FY2025 | Sep 30, 2025 | -$62.35M | – |
| Q2 FY2025 | Jun 30, 2025 | -$55.51M | – |
| Q1 FY2025 | Mar 31, 2025 | -$59.07M | – |
| Q4 FY2024 | Dec 31, 2024 | -$46.18M | – |
| Q3 FY2024 | Sep 30, 2024 | -$46.63M | – |
| Q2 FY2024 | Jun 30, 2024 | -$47.98M | – |
| Q1 FY2024 | Mar 31, 2024 | -$46.06M | – |
| Q4 FY2023 | Dec 31, 2023 | -$63.37M | – |
| Q3 FY2023 | Sep 30, 2023 | -$54.50M | – |
| Q2 FY2023 | Jun 30, 2023 | -$84.83M | – |
| Q1 FY2023 | Mar 31, 2023 | -$74.62M | – |
| Q4 FY2022 | Dec 31, 2022 | -$74.07M | – |
| Q3 FY2022 | Sep 30, 2022 | -$79.48M | – |
| Q2 FY2022 | Jun 30, 2022 | -$92.07M | – |
| Q1 FY2022 | Mar 31, 2022 | -$95.77M | – |
| Q4 FY2021 | Dec 31, 2021 | -$93.05M | – |
| Q3 FY2021 | Sep 30, 2021 | -$67.54M | – |
| Q2 FY2021 | Jun 30, 2021 | -$55.91M | – |
| Q1 FY2021 | Mar 31, 2021 | -$50.56M | – |
| Q4 FY2020 | Dec 31, 2020 | -$46.84M | – |
| Q3 FY2020 | Sep 30, 2020 | -$36.66M | – |
| Q2 FY2020 | Jun 30, 2020 | -$26.78M | – |
| Q1 FY2020 | Mar 31, 2020 | -$25.72M | – |
| Q4 FY2019 | Dec 31, 2019 | -$16.18M | – |
| Q3 FY2019 | Sep 30, 2019 | -$12.73M | – |
| Q2 FY2019 | Jun 30, 2019 | -$11.81M | – |
| Q1 FY2019 | Mar 31, 2019 | -$8.46M | – |
| Q4 FY2018 | Dec 31, 2018 | -$9.36M | – |
| Q3 FY2018 | Sep 30, 2018 | -$6.38M | – |
| Q2 FY2018 | Jun 30, 2018 | -$5.09M | – |
| Q1 FY2018 | Mar 31, 2018 | -$5.55M | – |
| Q4 FY2017 | Dec 31, 2017 | -$9.76M | – |
| Q3 FY2017 | Sep 30, 2017 | -$3.98M | – |
| Q2 FY2017 | Jun 30, 2017 | -$6.74M | – |
| Q1 FY2017 | Mar 31, 2017 | -$5.04M | – |
See a number that looks wrong?